echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > STING Agonist Overview: Tumor Immunotherapy "Future Star"

    STING Agonist Overview: Tumor Immunotherapy "Future Star"

    • Last Update: 2020-07-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    STING (interferon gene stimulator, interferor ofon genes) is also known as MITA, TMEM73, ERIS, NET23, MPYS, etc., is currently a very popular target of drug research and developmentSTING AGON AS A CANCER, OBESITY, VIRAL INFECTION, LIVER INJURY, GLYCELIPID METABOLISM DISORDERS AND MANY OTHER DISEASES OF THE POPULAR EMERGING THERAPEUTIC DRUG RESEARCH DIRECTION, HAS ATTRACTED THE ATTENTION OF THE INDUSTRY, ESPECIALLY IN THE TREATMENT OF TUMORS, STING AGONISHASER AS IMMUNOTHERAPY HAS BECOME A VERY ACTIVE RESEARCH FIELDStING-related pathwaysSource: Reference Source 1Figure 1 shows STING-related action pathways, which show that they can promote anti-tumor action through the cGAS-STING pathwayStudies have shown that STING is primarily involved in the immune process in the fight against tumors, especially in the T-cell-mediated tumor immunity processResearchers have detected cGAS-STING pathways that effectively inhibit cancer cell metastasis in a variety of cancer-related diseases, including colon cancer, melanoma, and telomeraseRecent studies have found that NK cell-dependent tumor rejection also relies heavily on the activation of non-tumor cells STINGThe research of the relevant mechanism has given great prospect to target STING for the development of anti-tumor drugsFigure II STING agonists clinical researchat present, STING agonists anti-tumor drug development has made great progress, a number of drugs have entered clinical researchThese include IMSA-101, which is owned by Immune Sensor Therapeutics, GSK3745417 of GlaxoSmithKline, BMS-986301 of The Company, SB-11285 of Spring Bank Pharmaceuticals, and MK-1454 of MercatomIn terms of indications, it is currently mainly for solid tumors, but has also begun to develop non-solid tumors, such as MK-1454 for lymphomafigure three ring-shaped dinucleotide STING agoniser - ADU-S100from the molecular structure, the sting agonists currently under study can be divided into five main categories: Aring dinucleotides: cyclic dinucleotides as STING binding ligands, the activation of STING has a direct effect, ADU-S100 is the first clinical trial into the ring dinucleotides Class: This molecule was first developed by GlaxoSmithKline, which used the radioactively labeled cGAMP competition combined with high-throughput screening of the CTD region of the target STING, obtained a series of amino benzene and acetaminophen STING ago nists; It provides a new prospect for sting agonising agent developmentin general, there are more and more domestic and foreign intervention in STING agonists research, thanks to this, STING agonists continue to emerge, in the major disease treatment areas have made great progress Especially in the field of tumor immunotherapy, attracted the attention of many pharmaceutical giants, including Mercadong, 100-time Meimei Squibao, a number of drugs into clinical research I believe that in the future with the deepening of research, progress will be more and more rapid, look forward to the early market of this type of drugs, the benefit of the vast number of patients References: 1 Research Progress of cGAS-STING in metastasis, Acta Pharmacenica Sinica 2020, 55 (3): 398-406; 2.STING Agonising Research Progress, Chinese Journal of Pharmaceutical Chemistry, 2020; 3.Tumor-RexdcdG Triggers a STING-Sing Immunity, 2018, 49 (4): 754-763.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.